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Abstract Multiple sclerosis (MS) is an autoimmune disease
of unknown cause, in which chronic inflammation drives
multifocal demyelination of axons in both white and gray
matter in the CNS. The pathological course of the disease is
heterogeneous and involves an early, predominantly inflam-
matory demyelinating disease phase of relapsing–remitting
MS (RRMS), which, over a variable period of time, evolves
into a progressively degenerative stage associated with axonal
loss and scar formation, causing physical and cognitive dis-
ability. For patients with RRMS, there is a growing arsenal of
disease-modifying agents (DMAs), with varying degrees of
efficacy, as defined by reduced relapse rates, improved mag-
netic resonance imaging outcomes, and preservation of neu-
rological function. Establishment of personalized treatment
plans remains one of the biggest challenges in therapeutic
decision-making in MS because the disease prognosis and
individual therapeutic outcomes are extremely difficult to
predict. Current research is aimed at discovery and validation
of biomarkers that reliably measure disease progression and
effective therapeutic intervention. Individual biomarker can-
didates with evident clinical utility are highlighted in this
review and include neutralizing autoantibodies against DMAs,
fetuin-A, osteopontin, isoprostanes, chemokine (C-X-C motif)
ligand 13 (CXCL13), neurofilament light and heavy, and
chitinase 3-like protein. In addition, application of more
advanced screening technologies has opened up new catego-
ries of biomarkers that move beyond detection of individual
soluble proteins, including gene expression and autoantibody
arrays, microRNAs, and circulating microvesicles/exosomes.
Development of clinically useful biomarkers in MS will not
only shape the practice of personalized medicine but will also
serve as surrogate markers to enable investigation of innova-
tive treatments within clinical trials that are less costly, are of
shorter duration, and have more certainty of outcomes.
Key Points
In the past two decades several therapeutic options
have become available for patients with multiple
sclerosis. However, in individual patients it is
difficult to determine the effectiveness of a given
treatment because of the lack of objective measures
that define efficacy.
Recently, a number of candidate biomarkers have
emerged that can be used to measure ongoing
treatment response. These include determination of
protein levels that reflect disease activity and other
aspects of pathophysiological processes such as
oxidative stress and immune dysfunction as well as
neural degeneration. Application of these biomarkers
in clinical practice will help optimize therapeutic
decision making.
1 Biomarkers in Multiple Sclerosis
1.1 Overview of Multiple Sclerosis
Multiple sclerosis (MS) is a chronic illness of the central
nervous system (CNS) and is the leading non-traumatic
cause of disability in young adults. Worldwide, over
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2.3 million people suffer from MS. The disease is char-
acterized pathologically by an autoimmune attack directed
primarily at myelin, the protective insulation surrounding
nerve fibers in the brain and spinal cord. Demyelination,
axonal degeneration, and scar formation (sclerosis) are
characteristic of the inactive MS lesion. The clinical dis-
ease course consists of a several-year period of relapses
and remissions of neurological deficits (relapsing–remitting
MS [RRMS]) and evolves into a condition typified by
progressive disability (secondary progressive MS [SPMS]).
In a subset of patients (about 15 % of all patients with MS),
the disease course from clinical onset involves steady
worsening (primary progressive MS [PPMS]) [1].
The cause of MS is unknown, but multiple factors are
involved in its pathogenesis, where a combination of
genetics and environmental triggers are implicated. The
strongest genetic predisposition correlates with the major
histocompatibility complex, class II, DR beta 1 (HLA-
DRB1)*1501 allele, with some contribution from other
alleles, such as interleukin 2 receptor (IL2R) and interleu-
kin 7 receptor (IL7R) alleles [2]. Environmental agents
associated with MS include exposure to infectious organ-
isms (several candidate organisms have been investigated,
with Epstein–Barr virus being the most widely implicated
agent), vitamin D and its link to sunlight exposure and
geographical latitude, and, possibly, antigenic determinants
in the gut microbiome. Although an intrathecal cerebro-
spinal fluid (CSF) oligoclonal antibody response is seen in
approximately 90 % of patients with MS, the antigenic
trigger of this response remains unknown [1].
One of the complexities in understanding the patho-
genesis of MS is related to disease progression from RRMS
to SPMS. Unlike RRMS, which is associated with an
increasingly well-characterized immune response and
standardized magnetic resonance imaging (MRI) parame-
ters, SPMS exhibits the hallmarks of a neurodegenerative
phase, which is poorly understood and not easily quanti-
fied. Gray matter involvement, axonal degeneration, mi-
croglial activation, mitochondrial injury, and oxidative
stress are likely associated with MS progression [3]. Cur-
rently, there are no therapies that are effective in reversing
or slowing down the neurodegenerative process. Better
understanding of the underlying mechanisms that drive
disease progression will lead not only to discovery of new
therapeutic targets but also to identification of biomarkers
to measure disease progression, enabling more effective
management of progressive disease.
1.2 The Need for Biomarkers in Personalized Medicine
One of the biggest challenges in therapeutic decision-
making for MS is effective stratification (or personaliza-
tion) of treatment in the face of an uncertain prognosis. A
major objective at the time of the initial diagnosis is to
arrest the disease at the early inflammatory stage, with the
hope that this will also delay disease progression and
minimize future disability—a concept that has yet to be
proven clinically [4]. The growing list of disease-modify-
ing agents (DMAs) available to target inflammation in MS
includes b-interferons (IFNb), glatiramir acetate, natal-
izumab, and rituximab, as well as newer oral medications,
including fingolimod, teriflunomide, and dimethyl fuma-
rate. Treatment decisions based on the risk to benefit ratios
of each DMA are further complicated by the inherent
disease heterogeneity exemplified by different MS sub-
types and the rates of progression, the variety of clinical
presentations (spinal cord, cerebellar, optic neuritis, cog-
nition, fatigue, etc.), and the differences in pathological
subtypes, implying different disease mechanisms [5]. The
heterogeneity of MS is further reflected by the unpredict-
able efficacy of DMAs, which varies from patient to
patient. Identification and validation of predictive bio-
markers of therapeutic response are urgently needed to help
guide optimal treatment management strategies in patients
with MS.
At present, the clinical parameters that are used to assess
disease activity and therapeutic efficacy depend on relapses
rates, MRI outcomes, and changes in disability scores [1].
These assessments have limited sensitivity with respect to
subclinical disease activity, especially when related to gray
matter changes and spinal cord disease [6]. Effective
stratification of treatment for individual patients with MS
will ultimately depend on a new generation of assessment
tools with better accuracy and predictability. Thus, there is
a need for sensitive, specific, and relatively inexpensive
biomarkers that can detect disease activity and serve as
surrogate markers for assessing therapeutic efficacy [7].
For the purposes of this review, the definition of a bio-
marker is limited to measurable proteins, lipids, or nucleic
acids in body fluids (such as blood or CSF) that reflect a
disease-related or drug-related process. Some of the most
promising candidate biomarkers that meet these criteria are
listed in Table 1 and are discussed below. Despite the use
of MRI in MS diagnosis, disease activity assessment, and
therapeutic efficacy, a discussion of imaging techniques
falls outside the scope of this review. Ultimately, accurate
and sensitive biomarkers of subclinical disease activity will
provide neurologists with more objective tools, in addition
to MRI, to better assess and predict therapeutic outcomes
in individual patients with MS.
1.3 Biomarkers in Blood and Cerebrospinal Fluid
Screening and clinical use of blood-based biomarkers has
distinct advantages in many diseases, including MS. Blood
collection is a minimally invasive procedure performed
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routinely by nursing personnel. Sampling can be carried
out in large cohorts of patients, as well as in healthy con-
trols, and can easily be repeated for use in longitudinal
studies. While serum biomarkers are suitable for evaluating
the peripheral immune targets of various DMAs in MS,
they may lack sensitivity in monitoring disease processes
in the CNS, particularly with respect to monitoring pro-
gressive disease and the effect of therapeutics aimed at
neuroprotection and remyelination. On the other hand, CSF
is ideally suited to monitoring CNS disease activity
because of its close proximity to sites of disease pathology.
Discovery and rigorous validation of candidate CSF bio-
markers has been limited because CSF collection via
lumbar puncture is a relatively invasive procedure, com-
pared with blood collection. In recent years, however, an
increasing number of CSF biomarkers have been investi-
gated that potentially reflect key pathological processes
underlying disease activity and disease progression in MS
[7]. With the increasing rate of discovery and the potential
clinical utility of CSF biomarkers, an international effort
led by MS researchers has called for standardization of
CSF processing, bio-banking, and definition of control
samples for comparison between studies [8, 9]. With the
understanding that CSF sampling may be necessary during
clinical trials testing neuroprotective agents, the majority
of patients with MS who have been polled indicated a
willingness to undergo lumbar puncture procedures in
order to participate [10]. Given the potential of CSF
biomarkers to mirror CNS pathology, it is likely that CSF
sampling and biomarker analysis will be incorporated into
clinical research studies and into routine clinical care for
MS [10, 11].
2 Candidate Biomarkers of Therapeutic Response
2.1 Neutralizing Antibodies
Detection of neutralizing antibodies (NAbs) to DMAs in
MS continues to be one of the more clinically utilized
biomarkers in therapeutic decision-making. All protein-
based DMAs are potentially immunogenic—in some cases,
leading to development of antibodies that neutralize drug
activity. IFNb preparations are considered a well-tolerated
first-line therapy for RRMS, with efficacy in reducing
clinical relapses by 30 %. Clinical experience shows that
approximately 60 % of patients respond to IFNb and are
able to control their disease with prolonged IFNb therapy.
The remaining 40 % are categorized as non-responders
[12]. Many initial responders to IFNb can develop NAbs to
the drug 4–6 months after beginning the therapy, affecting
the efficacy of the drug [13]. The incidence of NAb
development is dependent on the type of IFNb, as well as
the route of administration, ranging from 4 % incidence
with intramuscular IFNb-1a to up to 47 % incidence with
subcutaneous IFNb-1b [14]. In combination with other
Table 1 Candidate biomarkers of therapeutic response in multiple sclerosis (MS)
Biomarker Description Utility in MS
NAbs NAbs to IFNb and natalizumab Serum NAb testing is used to support lack of response to IFNb
or natalizumab
Fetuin-A Secreted glycoprotein elevated in CSF of patients with MS;
fetuin-A expression is associated with MS-specific brain
pathology
CSF biomarker of subclinical disease activity and therapeutic
response to natalizumab
Osteopontin Matrix protein with pleiotropic functions, including pro-
inflammatory cytokine; secreted by activated immune cells
and abundantly expressed in MS lesions
CSF biomarker of disease activity, intrathecal inflammation,
and therapeutic response to natalizumab
8-iso-
PGF2a
Isoprostane byproduct of lipid peroxidation and a readout of
oxidative stress; CSF 8-iso-PGF2a levels are elevated in a
subset of patients with MS
CSF biomarker of oxidative stress, with possible predictive
value for therapeutics targeting oxidative pathways
CXCL13 B-cell chemokine elevated in CSF of patients with MS,
indicative of humoral responses
CSF biomarker of intrathecal B-cell response; potential
biomarker of therapeutic response to rituximab and
natalizumab
NFL/NFH Axonal proteins elevated in CSF as a result of axonal injury CSF NFH is a possible biomarker of accumulated axonal
damage in progressive MS; CSF NFL is a possible biomarker
of reduced axonal damage after natalizumab or rituximab
CHI3L1 Chitinase 3-like protein elevated in CSF of patients with CIS
who convert to RRMS; expressed by microglia and astrocytes
in brains of patients with MS
Prognostic CSF biomarker of conversion from CIS to RRMS;
possible biomarker of therapeutic response to natalizumab
8-iso-PGF2a 8-iso-prostaglandin F2a, CHI3L1 chitinase 3-like 1, CIS clinically isolated syndrome, CSF cerebrospinal fluid, CXCL13 chemo-
kine (C-X-C motif) ligand 13, IFN interferon, NAbs neutralizing antibodies, NFH neurofilament heavy, NFL neurofilament light,
RRMS relapsing–remitting multiple sclerosis
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assessments of clinical/MRI disease activity, NAb testing
can inform clinical decisions when IFNb discontinuation is
being considered because of lack of a sufficient therapeutic
response.
Although natalizumab is humanized, it is also immu-
nogenic. Like IFNb NAbs, NAbs against natalizumab can
also develop early during treatment, within 6 months [15].
Depending on the study, between 4.5 and 14.1 % of na-
talizumab-treated patients with MS have tested positive for
anti-natalizumab antibodies anytime during the treatment,
with 1–4.7 % of patients showing transient positivity and
3.5–9.4 % of patients showing persistent positivity [15–
17]. In addition, NAb positivity was associated with
reduced serum levels of natalizumab, an increased inci-
dence of infusion reactions such as hypersensitivity, and
reduced therapeutic efficacy [15, 18]. While NAbs against
natalizumab can be useful in identifying a failed thera-
peutic response to natalizumab, better biomarkers are
needed to more accurately classify drug non-responders.
The necessity of rapid recognition of an inadequate thera-
peutic response to natalizumab is underscored by the
increased risk (1:200) of developing the potentially fatal
side effect of progressive multifocal leukoencephalopathy
with a longer treatment duration of greater than 24 months
[19]. CSF fetuin-A (discussed below) [20] and circulating
CD49d expression [21] are emerging as candidate bio-
markers for accurate and timely determination of the
therapeutic efficacy of natalizumab.
2.2 Biomarkers of Disease Activity
The overall clinical management of patients with MS and
accurate assessment of therapeutic interventions would be
greatly improved by establishment of a universally agreed
upon reliable biomarker(s) of disease activity. At present,
our clinical parameters for measuring disease activity are
rudimentary and depend on relapses or changes in dis-
ability scores. Serial brain MRI scans are helpful in mon-
itoring disease activity over time, but patients may worsen
clinically without discernible activity on MRI. Further-
more, for spinal cord disease, MRI is even less sensitive in
detecting disease activity. Reliable biomarkers reflecting
subclinical disease have the potential to serve as surrogate
markers of disease activity for future clinical trials,
enabling more rapid and cost-effective development of new
MS therapies.
Over the past decade, proteomic-based technologies
have been used for unbiased CSF biomarker discovery in
MS (reviewed in [22]). Though many of the candidate
biomarkers have been validated independently, their clin-
ical utility remains unclear. One exception is fetuin-A
(alpha-2-HS-glycoprotein), a secreted glycoprotein origi-
nally found during a proteomic analysis of CSF from
patients with MS and disease controls [23]. Altered levels
of fetuin-A in CSF were associated with early conversion
to RRMS [24, 25]. Fetuin-A was also elevated in CSF from
subjects with SPMS but not in CSF from subjects with
PPMS [23, 26]. Fetuin-A is an abundant serum protein
secreted primarily from the liver in the adult [27]. In the
CNS, fetuin-A is absent in the normal adult brain but is
expressed during fetal brain development and is present at
high levels in fetal CSF, suggesting a role for fetuin-A
during CNS development [28–30]. In MS, CSF fetuin-A
was measured in 100 patients who were clinically catego-
rized as having either active or inactive disease, as defined
by a recent relapse, a change in the disability score, or a
change in MRI outcomes [20]. Elevation of CSF fetuin-A
levels significantly correlated with inflammatory disease
activity in patients with MS [20]. Fetuin-A was also ele-
vated in the CNS of mice with experimental autoimmune
encephalomyelitis (EAE), a commonly used animal model
of MS [20].
A valuable clinical application of CSF biomarkers is
their use as surrogate markers for assessing therapeutic
efficacy [7]. In that vein, the clinical utility of CSF fetuin-A
levels in determining therapeutic response to natalizumab
was investigated in a cohort of 77 patients with MS treated
with natalizumab longitudinally for 1 year. The decrease in
CSF fetuin-A levels in natalizumab-treated patients was
highly significant over 6 and 12 months, compared with
baseline pre-treatment levels [20]. The decline in CSF
fetuin-A levels was even more pronounced in patients who
were classified as treatment responders, compared with
non-responders, who showed no significant change in fet-
uin-A levels. Overall, these studies support the clinical
application of CSF fetuin-A as an objective and accurate
laboratory measure of disease activity and treatment effi-
cacy. These studies also highlight the potential of CSF
fetuin-A to be used in a routine clinical setting to support
MRI results in the therapeutic decision-making process.
Prior to clinical implementation of CSF fetuin-A as a
biomarker, validation studies would be required, showing a
correlation with disease activity in an independent cohort
of patients. In addition, the specificity of CSF fetuin-A for
MS in relation to other inflammatory diseases should be
defined. Finally, the decrease in CSF fetuin-A levels
described in natalizumab-treated patients would have to be
extended to therapeutic responses to other DMAs.
Other studies have identified additional CSF biomarkers
that are altered in patients with MS treated with DMAs,
and include chemokine (C-X-C motif) ligand 13
(CXCL13) [31] and neurofilament [32–34] (both discussed
below), as well as hepatocyte growth factor (HGF) [35] and
osteopontin [36, 37]. Osteopontin, in particular, has been
analyzed extensively in both blood and CSF from patients
with MS, as a biomarker of disease activity. Osteopontin is
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a pleotropic, pro-inflammatory cytokine secreted by acti-
vated immune cells and is expressed abundantly in MS
lesions [38]. Osteopontin levels are elevated in plasma
from patients with MS compared with controls, and have
been shown to correlate with DMA treatment [39, 40].
Subsequent studies, however, have shown that circulating
osteopontin levels are not specific enough to differentiate
MS disease activity from that of other concurrent disorders;
thus, osteopontin is not likely to be useful as a biomarker in
a clinical setting [41, 42]. CSF osteopontin levels were also
elevated in all subtypes of MS and correlated significantly
with clinical severity [36, 43–45], despite a lack of speci-
ficity for MS compared with other inflammatory neuro-
logical diseases [46]. As a biomarker of therapeutic
response, CSF osteopontin levels were reduced in patients
with RRMS or SPMS treated with natalizumab [20, 34,
37]. These studies suggested that CSF osteopontin may be
used along with other CSF biomarkers, such as fetuin-A
and CXCL13, to assess therapeutic effects on intrathecal
inflammation. Additional studies analyzing biomarker
panels in CSF are warranted, given their potential for use in
a clinical trial setting to assess the therapeutic efficacy of
natalizumab and other DMAs.
Interestingly, HGF, which has been shown to prevent
autoimmunity and contribute to CNS repair, has been
inversely correlated with disease activity [35]. CSF HGF
may reflect endogenous repair processes that take effect in
response to immunomodulation, suggesting its potential
utility as a surrogate biomarker for neuroprotection and
repair. Although these biomarkers await independent val-
idation in a larger number of patients with a clinically
confirmed drug response, they point the way to develop-
ment of a CSF biomarker panel that would greatly assist in
therapeutic decision-making with regard to the efficacy of
DMAs. This is especially relevant in patients with pro-
gressive MS, where DMA effects on disease activity and
intrathecal inflammation are more difficult to assess by
MRI [34].
2.3 Biomarkers of Oxidative Stress
Normal brain activity is associated with high oxygen
consumption relative to that of other tissues; thus, it is
highly vulnerable to a buildup of reactive oxygen species.
Because of the high lipid content of myelin, increased free
radical production as a consequence of oxidative stress can
also lead to lipid peroxidation [47]. In MS, inflammation,
demyelination, and neurodegeneration can increase the
level of metabolic and oxidative stress, which in turn likely
contribute to disease progression [3]. Biomarkers indica-
tive of oxidative stress pathway activity would help
quantify the impact of oxidative stress on disease pro-
gression in MS.
The isoprostane 8-iso-prostaglandin F2a (8-iso-PGF2a)
is a well-recognized readout of oxidative stress and lipid
peroxidation, which is generated by free radical-catalyzed
peroxidation of arachidonic acid in membrane phospho-
lipids. Increased levels of 8-iso-PGF2a have been detected
in urine and plasma from patients with MS [48, 49]. More
recently, CSF levels of 8-iso-PGF2a were tested in 241
patients with MS and were found to be significantly ele-
vated in both RRMS and progressive MS [50]. Interest-
ingly, distinct subsets of patients had normal 8-iso-PGF2a
levels (\20 pg/ml), moderately elevated levels (20–80 pg/
ml), and highly elevated levels ([100 pg/ml). Highly ele-
vated CSF 8-iso-PGF2a levels were observed in 31 % of
patients with SPMS, identifying a subset of patients with
progressive MS that exhibited quantifiable evidence of
oxidative stress [50]. These findings suggest that oxidative
stress may not be a universal phenomenon in all forms of
MS but may be a particular manifestation of inflammatory
neurodegeneration. With the advent of medications that
target oxidative pathways, such as dimethyl fumarate,
measurement of CSF isoprostanes may help define a group
of patients that would be most likely to benefit from this
class of therapeutics. Furthermore, measuring CSF 8-iso-
PGF2a levels may help identify other DMAs that may
indirectly affect oxidative stress by decreasing inflamma-
tion. Although these preliminary observations on CSF
8-iso-PGF2a levels are of interest, a number of additional
studies need to be performed to define the specificity and
sensitivity of isoprostane measurement. In addition,
mechanistic and pathological studies would be needed to
validate the use of isoprostanes as a biomarker of oxidative
stress in MS.
2.4 Biomarkers of B-Cell Involvement in the Central
Nervous System
CXCL13 is a potent B-cell chemoattractant, which is
emerging as a promising CSF biomarker that is indicative
of the humoral immune response in the CNS. Numerous
studies have now described elevated levels of CXCL13 in
CSF from patients with MS, as well as in CSF from
patients with other neuroinflammatory diseases [31, 51–
55]. Elevated CSF CXCL13 has been observed in early MS
(clinically isolated syndrome [CIS]), where it was associ-
ated with an increased risk of conversion to clinically
definite MS [52, 56]. CSF CXCL13 was also higher during
RRMS, where it correlated with indicators of more severe
disease course, such as the relapse rate, HLA genotype, and
immunoglobulin (Ig)-G index [52, 55, 57], further sup-
porting the use of CXCL13 as a prognostic biomarker in
MS. In addition, the use of CXCL13 as an indicator of
intrathecal B-cell responses in MS is supported by its
correlation with the number of B cells/plasmablasts, the
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IgG index, and the presence and number of oligoclonal
bands in the CSF [51–55, 58]. The reproducibility of these
data suggests that CXCL13 may indeed be a robust and
sensitive indicator of the degree of the humoral response in
the CNS.
The correlation between CXCL13 levels and B-cell
involvement in the CNS suggests that CXCL13 may have
clinical utility in measurement of the therapeutic efficacy of
B-cell–targeting therapies. B cells play an important role in
MS, which is highlighted by the polyspecific intrathecal
B-cell response observed as oligoclonal bands in the CSF and
is considered a diagnostic biomarker of MS. More recently,
the discovery that clinical progression (along with more
severe cortical pathology in the brains of subjects with MS) is
associated with ectopic meningeal B-cell follicles further
underscores the role of B cells in the disease pathogenesis
[59, 60]. Not surprisingly, CXCL13 has been shown to be
abundantly expressed within ectopic lymphoid tissue [60].
Rituximab, a B-cell–depleting anti-CD20 antibody therapy
(which is currently used off label for treatment of MS [61–
63]) has been reported to have some efficacy in disease
progression. Importantly, CXCL13, along with chemokine
(C-C motif) ligand 19 (CCL19), was shown to be signifi-
cantly reduced in CSF after rituximab treatment, correlating
with reduced B-cell and T-cell numbers [64]. Although
baseline CXCL13 or CCL19 levels in a small subset of rit-
uximab-treated patients did not predict therapeutic response
[65], the use of CXCL13 and/or CCL19 as a biomarker for
use in rituximab therapy remains promising for selection of
patients who might benefit from the treatment, and for
determination of therapeutic response longitudinally. In
terms of other MS therapies, CXCL13 has been reported to
be reduced in patients after treatment with natalizumab or
methylprednisolone, suggesting that it may have broader
utility as a biomarker of therapeutic response [31].
2.5 Biomarkers of Axonal Damage
Neurofilaments are major components of the axonal cyto-
skeleton, which exist as heteropolymers of low (NFL),
medium (NFM), and high (NFH) molecular weight protein
subunits. As a result of axonal injury, neurofilament pro-
teins are released into the extracellular space [66]; thus,
their levels in CSF are thought to reflect the degree of
axonal damage in neurodegenerative disease. In patients
with MS, CSF levels of both NFH and NFL have been
shown to be elevated and were highest during relapses,
reflecting acute axonal damage mediated by inflammatory
mechanisms in the CNS [67, 68]. In patients with CIS, CSF
NFL levels correlated with inflammatory outcomes, such as
gadolinium-enhancing lesions, and were predictive of
conversion to clinically definite MS and more severe long-
term disability outcomes [68, 69]. CSF NFL levels, in
particular, may reflect the level of acute axonal injury in
early MS, and may thus have some prognostic value in
determining disease outcomes, although these findings
require validation in a larger population.
In studies of progressive MS, CSF NFH levels remained
elevated and correlated with physical disability and chan-
ges in brain volume over 1 year, but they did not correlate
with the T2 lesion load, suggesting that NFH levels might
be an indicator of ongoing neurodegeneration [67, 70, 71].
Importantly, CSF NFH levels also correlated strongly with
age, possibly reflecting underlying age-related neurode-
generation [67]. Nevertheless, in age-corrected samples,
the dissociation of NFH levels with many (though not all)
inflammatory outcomes that were tested [67] provides
encouraging evidence that testing of CSF NFH levels,
along with CSF NFL levels, may help quantify the accu-
mulation of axonal damage in patients with MS.
As a potential indicator of axonal loss in MS, studies are
now looking at NFL and NFH levels in CSF after admin-
istration of DMAs. Natalizumab-treated patients exhibited
a 3-fold reduction in CSF NFL levels after 6–12 months,
suggesting that effective immunomodulatory therapies are
associated with reduced axonal damage [33]. Similarly,
patients with progressive MS treated with rituximab, na-
talizumab, or mitoxantrone also showed a significant
reduction in CSF NFL levels after treatment [32, 34].
Unfortunately, these studies were unable to show data
correlating CSF NFL levels with the treatment effect. In
addition, because rituximab, natalizumab, and mitoxan-
trone all target immune mechanisms, the observed reduc-
tion in NFL levels is presumably only secondary to
immunomodulation; thus, treatment effects on axonal
damage are only correlative. As new treatments targeting
neuroprotection and remyelination come through the
pipeline in the next decade, CSF neurofilament levels will
likely be a critical readout for therapeutic effects.
Prior to widespread adoption of CSF NFL or NFH
testing, issues remain regarding the availability and
reproducibility of the tests themselves. Studies have sug-
gested that neurofilament protein instability and potential
for aggregate formation may result in test result variability
and possible misinterpretation of data [9, 72, 73], although
a more recent analysis concluded that neurofilament pro-
teins in CSF are indeed stable [74]. In contrast to NFL,
there are no commercially available immunoassays for
NFH, requiring significant laboratory setup for its use in
the clinical setting. The multicenter effort to validate CSF
processing protocols, as well as the NFL immunoassay
(UmanDiagnostics NF-light), serves as a template for
adoption of other biomarkers like NFH, which will inevi-
tably be used as outcomes in future clinical trials.
Finally, antibodies to NFH and NFL have also been
detected in CSF and have been shown in some cases to be
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indicative of neurodegeneration in response to a humoral
response to axonal proteins [75]. Levels of CSF anti-NFL
antibodies detected by antigen microarray are reduced in
response to steroid treatment [76]. However, in previous
studies, anti-neurofilament autoantibodies have not con-
sistently correlated with specific clinical variables [77–80],
perhaps because of the variety of antigens used for neu-
rofilament autoantibody detection.
2.6 Prognostic Biomarkers
Chitinase 3-like 1 (CHI3L1) is a chitin-binding protein,
which lacks enzymatic activity and is known to play a role
in chronic inflammation and tissue injury [81]. Multiple
studies have identified elevated CSF CHI3L1 levels in
patients with MS as the result of an unbiased proteomic
screen of CSF samples [82–84]. In a study of patients with
CIS, elevated CSF CHI3L1 levels were associated with a
risk of conversion to clinically definite MS [82]. This study
suggested that CSF CHI3L1 may have potential use as a
prognostic biomarker in MS, although elevated CSF
CHI3L1 levels were not specific to MS [82]. More
recently, CHI3L1 and chitinase 3-like 2 (CHI3L2) were
identified as potential diagnostic biomarkers, since the
levels of both were elevated in the CSF of patients with
RRMS, compared with controls, and were confirmed as
correlating with more rapid conversion from CIS [84]. In
patients with MS and optic neuritis, CSF CHI3L1 levels
correlated with dissemination in space on MRI, suggesting
that CHI3L1 may hold prognostic value for disability
progression in MS after relapse [85]. The expression of
CHI3L1 in reactive astrocytes in MS and EAE lesions
suggests that CSF CHI3L1 levels may be a reflection of
astrogliosis [84, 86]. Interestingly, proteomic profiling of
CSF before and after natalizumab treatment for 1 year
showed that CSF CHI3L1 levels were significantly
reduced, suggesting the potential for use of CHI3L1 as a
biomarker of therapeutic response [83]. On the basis of
these promising early studies, further studies will be nee-
ded to determine the prognostic value of CSF CHI3L1
levels, requiring further validation in longitudinal samples
from a larger cohort of patients with MS.
3 Emerging Biomarker Categories
3.1 Transcriptomic Signatures
Gene expression profiling—or ‘‘transcriptomics’’—of
peripheral blood has been used extensively to identify
biomarkers for diagnosis, disease activity, and progression
of MS [87–89]. To date, conclusions from these studies
have been limited by lack of reproducibility and small
sample sizes. The approach is also limited because of
heterogeneity of gene expression changes in peripheral
blood that is unrelated to MS disease status. More recently,
researchers have focused their gene expression profiling on
specific immune cell subsets in MS with the hope of
increasing the signal to noise ratio [90].
Assessment of the molecular signatures associated with
therapeutic responses in MS—specifically, the response to
IFNb—has been somewhat more productive. In many
patients taking IFNb therapies, there is no correlation
between NAbs and lack of therapeutic response. Thus, one
of the biggest challenges in using IFNb as a first-line
therapy for MS continues to be accurate prediction and
assessment of therapeutic response. The search for a bio-
marker of IFNb response has proven even more difficult,
since the precise mechanism of action in MS remains
unclear. On the basis of the clinical need to predict IFNb
response in individual patients, numerous studies have
attempted to define specific molecular signatures in
peripheral blood that differentiate responders from non-
responders. Large-scale gene expression profiling has
revealed that clinical non-responders exhibit altered
expression of IFN-response genes, both at baseline and
after IFNb treatment [91–93]. These studies have revealed
differences in genes related to IFNb signaling, such as
signal transducer and activator of transcription 1, 91kDa
(STAT1), as well as genes related to Toll-like receptor 4
signaling in monocytes [94, 95]. In addition, lack of IFNb
response was found to correlate with more aggressive
T helper-17–mediated disease and elevated serum IL17F
levels [96]. Unfortunately, the ability of serum IL17F
levels to predict IFNb response could not be validated in a
larger independent cohort of IFNb-treated patients with MS
[97]. The discrepancy in these studies highlights some of
the challenges faced in biomarker validation, including
lack of standardized clinical definitions for poor treatment
response in individual patients, as well as the complexities
surrounding the therapeutic mechanisms of IFNb, despite
the fact that this was the first treatment to show efficacy in
MS.
Recently, more advanced technologies have been
applied to the quest for predictive biomarkers of IFNb
response. Next-generation sequencing (RNA-seq) was
recently used to interrogate whole-blood transcriptomes of
untreated and IFNb-treated patients with MS [98]. A single
marker was validated—ribosomal protein S6—which was
reduced in IFNb responders. Another study profiled micr-
oRNA (miRNA) expression changes in response to IFNb
and found specific downregulation of the miR-29 family of
miRNAs [99]. Though encouraging, these studies were
plagued by the same challenges in clinical biomarker val-
idation as mentioned above. Until more is understood
regarding the mechanism by which IFNb benefits certain
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patients with MS, the search for a predictive biomarker of
therapeutic response may remain a fishing expedition.
3.2 Circulating MicroRNAs
MiRNAs are short, single-stranded, non-coding RNA
molecules, which modulate gene expression and protein
synthesis. They regulate approximately 30 % of genes;
thus, they play an important role in many physiological and
pathological processes, including those related to autoim-
munity and neurodegeneration [100]. Several recent studies
have examined the involvement of circulating miRNAs in
MS, aiming to uncover important pathological pathways
related to MS and to identify potential biomarkers. Ini-
tially, a number of miRNA species were found to be dif-
ferentially expressed in patients with MS compared with
controls, and to have the potential for use as diagnostic
biomarkers or biomarkers of disease progression. MiRNAs
have been profiled from peripheral blood mononuclear
cells [101, 102], serum [103], plasma [104, 105], whole
blood [106], and CSF [107] from patients with MS, with a
variety of results, reflecting the different sampling mate-
rials that were used. As miRNA screening evolves, addi-
tional studies will need to be carried out with more
homogenous patient populations and standardized tech-
nologies in order to reproducibly identify specific miRNAs
as MS biomarkers.
Recent studies have used miRNA profiling to better
understand treatment effects, with the hope of identifying
biomarkers of therapeutic response. As mentioned in the
previous section, the reduction of miR-29 miRNA was
associated with IFNb response [99]. In another study, a
B-cell miRNA signature was determined from patients
with RRMS who were either untreated or treated with
natalizumab [101]. Although some differentially expressed
miRNAs were found in natalizumab-treated patients (all of
whom were responders), the relevance of this finding is
unclear, since natalizumab does not target B cells specifi-
cally. Using a slightly different approach, another study
analyzed pre-selected miRNAs that were previously iden-
tified as playing a role in the immune response. In patients
with RRMS treated with glatiramir acetate, two miRNAs
appeared to be reduced to control levels when compared
with those of untreated or IFNb-treated patients [108].
Although this study will require validation in glatiramir
acetate-treated patients followed longitudinally, it does
suggest that therapeutic response may be reflected by res-
toration of dysregulated miRNAs.
3.3 Exosomes/Microvesicles
One of the biggest challenges in identification of bio-
markers for pathological mechanisms in the CNS during
MS is the inaccessibility of the diseased tissue. Cerebral
biopsies are extremely rare, and imaging techniques are not
sensitive enough to detect pathological processes at the
cellular level. Many secreted biomolecules, such as cyto-
kines, are readily detected in bodily fluids, including CSF,
and can serve as important biomarkers of inflammatory
status. However, secreted biomolecules originating from
non-circulating CNS cell types, such as neurons, oligo-
dendrocytes, astrocytes, and microglia, are often present in
very low concentrations and thus are difficult to detect. In
recent years, better understanding of cell-to-cell signaling
through secreted microvesicles has suggested that micro-
vesicles may be an important source of biomarkers in many
different diseases [109]. Secreted microvesicles, including
smaller vesicles referred to as exosomes, are loaded with a
cargo of proteins, RNAs, and miRNAs, which are trans-
ported to recipient cells, resulting in altered gene expres-
sion and protein content. Microvesicles/exosomes have a
variety of biological functions, including an active role in
intercellular communication in the immune system, where
they carry antigens or MHC–peptide complexes, and
induce antigen-specific immune responses [110]. In the
CNS, microvesicles are thought to play a role in synaptic
plasticity, axonal/glial communication, and antigen transfer
[111]. Research investigating the role of microvesicles/
exosomes in MS is ongoing and aims to identify micro-
vesicle-associated RNA and proteins that reflect ongoing
demyelination and neurodegeneration.
Microvesicles are most commonly isolated by ultra-
centrifugation and are present in most bodily fluids,
including CSF. To date, few studies have examined
microvesicle populations in CSF during MS disease onset
and progression. Over 20 years ago, microvesicles detected
in MS CSF were found to originate from injured oligo-
dendrocytes, where they play a possible role in myelin
destruction [112]. More recently, CSF microvesicles posi-
tive for the myeloid cell marker IB4 were associated with
neuroinflammation both in patients with MS and in patients
with neuromyelitis optica or other inflammatory diseases
[113]. In EAE, myeloid-derived microvesicles have been
shown to be capable of promoting neuroinflammation,
suggesting that microvesicle shedding may play a patho-
genic role, at least in EAE [113]. Interestingly, fingolimod
treatment reduced myeloid-derived microvesicles in the
CSF of mice with EAE, suggesting that myeloid-derived
microvesicles may be a therapeutic biomarker and possibly
a therapeutic target of this agent [113].
Despite the exciting potential of exosomes in various
clinical applications and as a source of biomarkers, many
challenges remain. There is a lack of consistent criteria by
which to characterize exosomes, which can vary on the
basis of the method of purification, the source material, and
the method of biomarker detection [114]. As the field
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evolves, the ability to normalize the size and yield of
purified microvesicles will be critical for biomarker dis-
covery and validation in diseases such as MS.
3.4 Antigen Arrays
The adaptive autoimmune response in MS results in clonal
expansion of B cells in the CNS, producing the charac-
teristic oligoclonal immunoglobulin bands that are present
in the CSF of patients with MS. Better understanding of the
autoantibody repertoire in MS would not only help identify
disease-causing antigens and potential therapeutic targets,
but would also aid in the discovery of new biomarkers (or
biomarker signatures) of disease. The development of
microarray-based technologies has allowed for high-
throughput analysis of autoantibody reactivity [115].
Analysis of autoantibody signatures in the serum of
patients with MS has allowed for discrimination between
different stages and pathological processes in MS [116].
More recently, antigen microarrays have been used to
identify antibody signatures in CSF [76], allowing for a
more specific approach to analyze the intrathecal immune
responses that drive disease progression. Patients with
RRMS had a CSF-specific antibody response directed
against various CNS antigens [76, 117], which was reduced
after treatment with methylprednisolone [76]. In addition,
use of lipid-based and carbohydrate-based antigen arrays is
uncovering additional autoantibody signatures in MS CSF
[118–120]. Surprisingly, the CSF antibody signature
showed significant heterogeneity between patients, which
may be due in part to detection of non-pathogenic auto-
antibodies as a result of arrays composed of recombinant
proteins. Nevertheless, CSF antibody signatures have the
potential to be used as biomarkers for diagnostic accuracy,
to monitor disease progression, and to aid in decision-
making regarding therapy.
4 Clinical Use of Biomarkers in the Management
of Multiple Sclerosis
The past two decades have seen the emergence of a number
of therapeutic options for patients with MS. With rising
expectations, complete cessation of disease activity is
becoming a desirable goal. Clinical application of reliable
biomarkers will likely make this feasible, as it will be
possible to assess the effectiveness of a treatment modality
objectively even in the absence of clinical deterioration. At
present, the clinical use of NAbs to IFNb as a biomarker is
established. In addition, it is likely that with the current
validation studies that are ongoing, CSF analysis of fetuin-
A and other markers, such as osteopontin, will be used
routinely in MS clinical centers. This will be particularly
helpful in determining therapeutic responses in patients
with progressive disease, in whom disease activity corre-
lates less well with current clinical measures, in compari-
son with patients with relapsing disease.
As the reliability of biomarkers becomes validated, their
use in clinical trials will greatly reduce the costs and duration
of phase III studies. Current trials frequently rely on surrogate
markers, such as MRI changes and relapse rates, which require
several hundred patients and a minimum study duration of
2–3 years. Use of biomarkers of disease activity that could
show significant changes after 6 months of treatment would
lead to shorter, less expensive drug trials in RRMS. Further-
more, biomarkers that could accurately reflect disease pro-
gression would overcome the real difficulty in assessing
outcomes in drug trials in SPMS and PPMS.
5 Conclusions
A lack of understanding of the cause of MS, as well as
disease heterogeneity, make it unlikely that one single
biomarker will satisfy the needs for disease monitoring in
MS. The identification of individual biomarker patterns is
rapidly evolving into more complex biomarker panels or
signatures. In this regard, significant progress has been
made since 2009 with respect to biomarker changes in
response to therapy [7]. The challenge of biomarker
development continues to be the lack of sensitivity and
reproducibility. Furthermore, these studies rely on a large
number of patients in an environment where research and
clinical practice are closely integrated. Despite these lim-
itations, continued progress in biomarker research has led
to early-stage clinical application of biomarkers in MS.
Optimal treatment of individual patients with MS will
ultimately require validated biomarker panels that are
capable of predicting and monitoring the efficacy of the
growing number of available therapeutic options.
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